| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/NAU.1001 |
| P8608 | Fatcat ID | release_nqxsmumxgjgvbotahmb76m5t5u |
| P698 | PubMed publication ID | 11385690 |
| P2093 | author name string | Edlund C | |
| Fall M | |||
| Knutson T | |||
| Dahlstrand C | |||
| P2860 | cites work | The bladder cooling reflex and the use of cooling as stimulus to the lower urinary tract | Q33777870 |
| Benign prostatic hyperplasia. Practical treatment guidelines | Q36859820 | ||
| Post-prostatectomy incontinence. A urodynamic and fluoroscopic point of view | Q37507316 | ||
| Prevalence of lower urinary tract symptoms in Austria as assessed by an open survey of 2,096 men. | Q39472669 | ||
| The pathophysiological changes in the bladder obstructed by benign prostatic hyperplasia | Q39487504 | ||
| Changes in Detrusor Innervation with Relief of Outflow Tract Obstruction | Q39504281 | ||
| Obstructive uropathy in the male | Q41029341 | ||
| Post-prostatectomy continence in the parkinsonian patient: the significance of poor voluntary sphincter control | Q44373739 | ||
| Subtypes of overactive bladder in old age. | Q48322351 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 237-247 | |
| P577 | publication date | 2001-01-01 | |
| P1433 | published in | Neurourology and Urodynamics | Q15753354 |
| P1476 | title | BPH with coexisting overactive bladder dysfunction--an everyday urological dilemma. | |
| P478 | volume | 20 |
| Q36628776 | Antimuscarinic therapy in men with lower urinary tract symptoms: what is the evidence? |
| Q39003669 | Bladder function in obstructed men - does age matter? |
| Q47614859 | Can Bladder Outflow Obstruction be Diagnosed From Pressure Flow Analysis of Voiding Initiated by Involuntary Detrusor Overactivity? |
| Q39309357 | Changes of bladder activity and connexin 43-derived gap junctions after partial bladder-outlet obstruction in rats. |
| Q39316979 | Changes of bladder activity and glycine levels in the lumbosacral cord after partial bladder outlet obstruction in rats. |
| Q37283712 | Characterization of overactive bladder in women in a primary care setting |
| Q46858361 | Cluster analysis and lower urinary tract symptoms in men: findings from the Boston Area Community Health Survey. |
| Q45100348 | Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder |
| Q34468683 | Correlation of male overactive bladder with intravesical prostatic protrusion |
| Q88636939 | Current consensus and controversy on the treatment of male lower urinary tract symptoms/benign prostatic hyperplasia |
| Q37049089 | Does anticholinergic medication have a role in treating men with overactive bladder and benign prostatic hyperplasia? |
| Q35635802 | Effect of Detrusor Overactivity on Functional Outcomes After Holmium Laser Enucleation of the Prostate in Patients With Benign Prostatic Obstruction. |
| Q35076886 | Effect of holmium laser enucleation of prostate on overactive bladder symptoms and urodynamic parameters: a prospective study. |
| Q33727733 | Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies |
| Q43140993 | Efficacy and safety of tolterodine extended release and dutasteride in male overactive bladder patients with prostates >30 grams |
| Q79990856 | Efficacy of tolterodine in preventing urge incontinence immediately after prostatectomy |
| Q93082910 | Epidemic investigation of benign prostatic obstruction with coexisting overactive bladder in Shanghai Pudong New Area and its impact on the health-related quality of life |
| Q91740901 | Epidemiology and treatment modalities for the management of benign prostatic hyperplasia |
| Q48247734 | Factors associated with continuing medical therapy after transurethral resection of prostate. |
| Q38480816 | Is There a Correlation Between the Presence of Idiopathic Detrusor Overactivity and the Degree of Bladder Outlet Obstruction? |
| Q53386633 | Low-Dose Anticholinergic Combination Therapy in Male Benign Prostatic Hyperplasia Patients with Overactive Bladder Symptoms. |
| Q44185745 | Mechanical stretch regulates cell survival in human bladder smooth muscle cells in vitro |
| Q51933134 | Medical therapy for benign prostatic hyperplasia: new terminology, new concepts, better choices. |
| Q46110279 | Mediterranean diet after prostate cancer diagnosis and urinary and sexual functioning: The health professionals follow-up study |
| Q100523538 | Mirabegron versus Placebo Add-on Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: a Safety Analysis from the Randomized, Phase 4 PLUS Study |
| Q35041139 | Models of inflammation of the lower urinary tract |
| Q37558389 | Nocturia is often inadequately assessed, diagnosed and treated by physicians: results of an observational, real-life practice database containing 8659 European and US-American patients |
| Q33610021 | Non-invasive parameters predicting bladder outlet obstruction in Korean men with lower urinary tract symptoms. |
| Q44125663 | Occurrence of overactive bladder in patients with benign prostatic hyperplasia in the Czech Republic |
| Q35586218 | Overactive bladder and men: Indications for anticholinergics |
| Q34993835 | Overactive bladder in the male patient: bladder, outlet, or both? |
| Q38634816 | Patient-perceived effectiveness and impact on quality of life of solifenacin in combination with an α-blocker in men with overactive bladder in Sweden: a non-interventional study |
| Q37586212 | Place of overactive bladder in male lower urinary tract symptoms |
| Q99566090 | Predictive value of preoperative comprehensive evaluation on the efficacy of HoLEP |
| Q33402658 | Prevalence, evaluation and management of overactive bladder in primary care |
| Q35043971 | Prostatic inflammation induces urinary frequency in adult mice |
| Q48060968 | Rate and associated factors of solifenacin add-on after tamsulosin monotherapy in men with voiding and storage lower urinary tract symptoms |
| Q42669501 | Tamsulosin and Solifenacin in the Treatment of Benign Prostatic Hyperplasia in combination with overactive bladder |
| Q41164717 | The predictive factors of α1-D/A adrenoceptor antagonist, naftopidil, dose increase therapy for male lower urinary tract symptoms caused by benign prostatic hyperplasia: INFORM study |
| Q35185796 | The role of urodynamics in the diagnosis and treatment of benign prostatic hyperplasia |
| Q33781988 | The urologist's view of male overactive bladder: discrepancy between reality and belief in practical setting. |
| Q48667074 | Treatment Patterns and Patient Reported Outcomes in Benign Prostatic Hyperplasia Patients with Overactive Bladder Symptoms |
| Q92189783 | Updating the evidence on drugs to treat overactive bladder: a systematic review |
| Q53251447 | Urodynamic predictors of outcomes with photoselective laser vaporization prostatectomy in patients with benign prostatic hyperplasia and preoperative retention. |
| Q81160842 | Videourodynamic analysis of pathophysiology of men with both storage and voiding lower urinary tract symptoms |
| Q37784482 | Vulnerable Elderly Patients and Overactive Bladder Syndrome |
| Q36608376 | When to use antimuscarinics in men who have lower urinary tract symptoms |
| Q84870663 | [Prevalence of lower urinary tract symptoms in patients with overactive bladder. Patient management in clinical practice] |
| Q80652847 | [The role of muscarinic receptor antagonists in the treatment of men with lower urinary tract symptoms secondary to BPH] |
Search more.